Petersen MW, et al. - In adults with serious bacterial infection of any origin, authors examined 1,753 subjects to analyze the patient-important advantages and disadvantages of empirical metronidazole vs placebo or no therapy in this systematic review with meta-analysis and trial sequential analysis. No difference in the primary outcome mortality (within 90 days) was observed. Secondary infections were seen in fewer candidates receiving metronidazole (relative risk 0.43). As the quality of evidence was very low for all consequences, they indicated a high risk of random errors due to a lack of data.